BioArctic’s Alzheimer’s Drug Lecanemab Wins Prestigious Bioindustry Award

BioArctic AB Class B ( ($SE:BIOA.B) ) has issued an update.

BioArctic AB’s partner Eisai announced that their co-developed Alzheimer’s drug, lecanemab (Leqembi®), has been awarded the 9th Bioindustry Award by the Japan Bioindustry Association. This recognition highlights the significance of lecanemab in altering the course of Alzheimer’s disease by targeting amyloid-beta proteins. Eisai leads the global development and commercialization efforts, with BioArctic having rights to commercialize in the Nordic region, indicating a strong market positioning and potential impact on stakeholders in the biopharmaceutical industry.

More about BioArctic AB Class B

BioArctic AB is a Swedish research-based biopharmaceutical company that focuses on developing innovative treatments for neurodegenerative diseases. The company is known for originating Leqembi® (lecanemab), the first drug proven to slow the progression of early Alzheimer’s disease and reduce cognitive impairment. BioArctic collaborates with Eisai on the development of Leqembi and has a broad research portfolio that includes Alzheimer’s, Parkinson’s, ALS, and enzyme deficiency diseases, utilizing their proprietary BrainTransporter™ technology.

Average Trading Volume: 258,937

Current Market Cap: SEK16.4B

See more data about BIOA.B stock on TipRanks’ Stock Analysis page.